In this study, researchers from the Netherlands identified prognostic factors for survival in patients with advanced esophageal cancer, treated with cisplatin-based combination chemotherapy.
The team analyzed the baseline characteristics of 350 patients who were treated in 6 consecutive prospective trials.
Patients were treated with either cisplatin/etoposide, cisplatin/etoposide/5-fluorouracil, cisplatin/paclitaxel (weekly), or cisplatin/paclitaxel (biweekly).
The team found that patients' overall median survival was 9 months.
|Median survival for patients with no risk factors was 12 months.|
|British Journal of Cancer|
They calculated the 1, 2 and 5-year survival rates as 33%, 12%, and 4%, respectively.
The researchers identified the main prognostic factors as WHO performance status, lactate dehydrogenase (LDH), extent of disease, and type of treatment.
Weight loss, liver metastases, and alkaline phosphatase were also identified using univariate analyses, but did not remain significant in multivariate analyses.
The team found that median survival for patients with none of the identified risk factors was 12 months.
Dr Polee's team concluded, "The performance status, extent of disease, LDH and the addition of paclitaxel to cisplatin are independent prognostic factors in patients with advanced esophageal cancer, who are treated with cisplatin-based combination chemotherapy".